Opens in a new tab

Hypoglycaemia (Low Blood Sugar): Symptoms, Causes and Treatment

Table of Content

Friendly woman with diabetes sitting on a park bench and checking her glucose meter while a smiling friend offers her a glass of juice, glucose tablets and a continuous glucose monitor sensor on the bench beside them

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

Hypoglycaemia means low blood sugar: a blood glucose level below 3.9 mmol/L (70 mg/dL). It is most common in people with diabetes who take insulin or certain diabetes pills, and it can develop quickly. Typical low blood sugar symptoms are shakiness, sweating, hunger, a fast heartbeat, irritability and confusion. Below 3.0 mmol/L (54 mg/dL), unclear thinking becomes more likely, and severe episodes can cause seizures or loss of consciousness.

The usual fix is the "rule of 15": take 15 grams of fast-acting sugar, such as 4 glucose tablets or half a glass (about 120 mL) of regular juice, wait 15 minutes and check again. If the person cannot swallow safely, glucagon (nasal or ready-to-use injection) is the emergency treatment. Without diabetes, true hypoglycaemia is rare and needs a medical workup.

Key takeaways

  • The American Diabetes Association (ADA) defines level 1 (below 3.9 mmol/L), level 2 (below 3.0 mmol/L) and level 3, a severe event needing another person's help.
  • Treat a conscious person with 15 grams of glucose, recheck after 15 minutes and repeat if still low.
  • Glucagon should be prescribed to everyone who takes insulin or is at high risk.
  • About 1 in 4 people with diabetes have impaired awareness of hypoglycaemia; a continuous glucose monitor (CGM) with alarms is recommended.
  • Without diabetes, doctors confirm the Whipple triad, then measure insulin, C-peptide, proinsulin and beta-hydroxybutyrate during an episode.

What is hypoglycaemia?

Glucose is the main fuel of the brain. Normally, when glucose starts to fall, the pancreas stops releasing insulin and releases glucagon, a hormone that tells the liver to release stored sugar. Adrenaline and cortisol add a second line of defence. A 2023 review explains that these counterregulatory defences make spontaneous hypoglycaemia uncommon in people not taking glucose-lowering medicines.

Hypoglycaemia happens when this balance fails: too much insulin (from an injection, a pill or a tumour), too little sugar coming in, or a liver that cannot release enough. To understand where 3.9 mmol/L sits on the scale, see our guide to glucose levels and normal ranges.

The three levels of hypoglycaemia

The ADA Standards of Care in Diabetes 2025 classify hypoglycaemia as follows:

  • Level 1: glucose below 3.9 mmol/L (70 mg/dL) and at or above 3.0 mmol/L (54 mg/dL).
  • Level 2: glucose below 3.0 mmol/L (54 mg/dL). This is clinically significant hypoglycaemia; symptoms affecting the brain become more likely, according to MedlinePlus.
  • Level 3: a severe event with altered mental or physical status, requiring another person's help, irrespective of the glucose level.

How common is it?

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) cites a global study of people on insulin: over 4 weeks, 4 in 5 people with type 1 diabetes and nearly half of those with type 2 diabetes had at least one low. Severe lows affect about 2 in 100 US adults with diabetes who use insulin or certain pills each year.

Low blood sugar symptoms

Symptoms are either "neurogenic" warning signs caused by adrenaline or "neuroglycopenic" signs of a brain short of glucose.

Early and mild to moderate symptoms

  • Shakiness, sweating, chills and pale skin
  • Hunger, a fast or irregular heartbeat, anxiety or irritability
  • Dizziness, lightheadedness, tiredness and headache
  • Confusion and trouble seeing or speaking clearly

Severe and nighttime symptoms

Cleveland Clinic lists blurred or double vision, slurred speech, poor coordination, seizures and loss of consciousness as signs of severe hypoglycaemia. During sleep, NIDDK describes nightmares, sweating that soaks the sheets and waking up tired or confused; some people do not wake up at all.

Causes of hypoglycaemia in people with diabetes

In diabetes, hypoglycaemia is usually a side effect of treatment. Our guide to diabetes symptoms, causes and treatment explains why insulin is needed in type 1 diabetes and often later in type 2 diabetes.

  • Insulin: too large a dose, the wrong type of insulin, or an injection into muscle instead of fat (Cleveland Clinic).
  • Sulfonylureas, such as glipizide, which push the pancreas to release insulin over several hours, and meglitinides, taken before meals (NIDDK). Many other diabetes medicines rarely cause lows on their own, MedlinePlus notes.
  • Skipping or delaying meals, not eating enough carbohydrates, or fasting while still taking glucose-lowering medicines.
  • Extra physical activity, which can lower glucose for up to 24 hours afterward.
  • Drinking alcohol without enough food.
  • An illness that stops you from eating or keeping food down.

Who is at highest risk?

The ADA's major risk factors are a level 2 or 3 episode in the past 3 to 6 months, intensive insulin therapy, impaired awareness, end-stage kidney disease and cognitive impairment, along with food insecurity and fasting for religious reasons. A 2025 meta-analysis of 31 studies (54,634 adults with type 1 diabetes) found that a history of hypoglycaemia doubled the odds of new episodes (odds ratio 2.31), while impaired awareness multiplied them by about 6.

Hypoglycaemia without diabetes

Low blood sugar in someone who does not take diabetes medicines is uncommon and should not be self-diagnosed. A home meter is not precise enough at low values: a 2025 review notes that 95% of readings from a given home meter fall within 15% of laboratory results. Doctors first confirm the Whipple triad:

  1. a low plasma glucose level, usually below 3.0 mmol/L (55 mg/dL) in people without diabetes;
  2. symptoms that fit hypoglycaemia at the same time;
  3. relief of those symptoms when glucose is brought back up.

Causes when insulin is too high

  • Insulinoma: a rare insulin-making tumour of the pancreas (fewer than 4 cases per million people per year), causing lows after fasting, often early in the morning; surgery is the usual cure.
  • Post-bariatric hypoglycaemia: lows 2 to 4 hours after meals, usually more than a year after gastric bypass or sleeve surgery; symptoms were reported in up to 30% of patients.
  • Noninsulinoma pancreatogenous hypoglycaemia, a rare disorder of the insulin-making cells of the pancreas.
  • Insulin autoimmune syndrome, caused by antibodies against insulin; insulin levels can exceed 1,000 pmol/L.
  • Hidden or accidental use of insulin or sulfonylurea pills.

Causes when insulin is low

  • Alcohol: 48 grams of alcohol can suppress the liver's sugar production by as much as 45%, especially after days of poor eating.
  • Adrenal insufficiency (low cortisol), found in 6% of people seen in one emergency department for hypoglycaemia symptoms. Our adrenal panel guide explains the tests.
  • Severe illness: sepsis, starvation, and advanced kidney, heart or liver failure, and deficiencies of growth hormone or thyroid hormone.
  • Tumors releasing IGF-2 (non-islet cell tumour hypoglycaemia): an IGF-2 to IGF-1 ratio above 20 was found in 94% of cases. See our IGF-1 blood test guide.
  • Some medicines: indomethacin, gatifloxacin, pentamidine, quinine and cibenzoline, plus unripe ackee fruit (2025 review).

Reactive hypoglycaemia

Reactive (postprandial) hypoglycaemia is a low 2 to 4 hours after eating, often after simple carbohydrates such as white bread, potatoes or pastries (Cleveland Clinic). After weight-loss surgery, the body can release too much insulin after meals; doctors separate this from "dumping syndrome". A 2025 review advises less than 30 grams of complex carbohydrates per meal, no simple sugars, and acarbose as an affordable first drug.

Diagnosis and lab workup

With diabetes, a meter or CGM reading confirms the low and the work is to find out why. Without diabetes, blood is drawn during an episode, before treatment, because the hormone pattern at that moment points to the cause.

Blood tests drawn during a low

  • Plasma glucose in a laboratory (not only a meter).
  • Insulin: see our insulin blood test guide.
  • C-peptide: released in equal amounts with the body's own insulin, but absent from injected insulin. Our C-peptide test page explains high and low results.
  • Proinsulin, the precursor of insulin, often high with insulinoma.
  • Beta-hydroxybutyrate (blood ketones): low when insulin is high, because insulin blocks ketone production.
  • A screen for sulfonylureas and other oral diabetes drugs in blood or urine.

Supervised fasting and meal tests

During a supervised 72-hour fast in the hospital, you drink only water and blood is taken regularly; the test stops when glucose falls to 3.0 mmol/L (54 mg/dL) or less or symptoms appear (2025 consensus). About 95% of people with insulinoma meet the end-of-fast criteria within 48 hours. For lows after meals, a mixed-meal test is used instead. Imaging, such as a CT scan, comes only after the blood tests.

Hypoglycaemia thresholds and lab criteria (SI and US units)

MeasureThreshold (SI units, mmol/L)Threshold (US units, mg/dL)What it means
Glucose, level 1 (diabetes)Below 3.9 and 3.0 mmol/L or moreBelow 70 mg/dL and 54 mg/dL or moreAlert value: treat with 15 g of glucose
Glucose, level 2 (diabetes)Below 3.0 mmol/LBelow 54 mg/dLClinically significant: treat now, review therapy
Level 3 (severe)Any valueAny valueNeeds another person's help; glucagon if unable to swallow
Glucose without diabetes (Whipple triad)About 3.0 mmol/LBelow 55 mg/dLLow enough to start a workup if symptoms match
Sensor glucose in pregnancyBelow 3.5 mmol/LBelow 63 mg/dLLow on a CGM during pregnancy (ADA)
Insulin during a low18 pmol/L or more3 µU/mL or moreInsulin not switched off: insulin-mediated low
C-peptide during a low0.2 nmol/L or more0.6 ng/mL or moreThe body is making the insulin (tumour, pills, surgery)
Proinsulin during a low5 pmol/L or more5 pmol/L or moreSupports endogenous hyperinsulinism
Beta-hydroxybutyrate during a low2.7 mmol/L or less2.7 mmol/L or lessKetones suppressed by insulin; higher values point to non-insulin causes
CGM time below range (most adults)Under 4% below 3.9 mmol/L; under 1% below 3.0 mmol/LUnder 4% below 70 mg/dL; under 1% below 54 mg/dLAbove these targets, therapy should be adjusted

The insulin, C-peptide, proinsulin and ketone criteria apply to blood drawn when glucose is 3.0 mmol/L or below (2025 reviews); laboratory ranges vary.

How to read the results

  • High insulin, low C-peptide and low proinsulin: insulin injected from outside the body.
  • High insulin, C-peptide and proinsulin with a negative drug screen: the body overproduces insulin (insulinoma, post-bariatric hypoglycaemia); with a positive screen, sulfonylurea pills.
  • Very high insulin (often above 1,000 pmol/L) with insulin antibodies: insulin autoimmune syndrome.
  • Low insulin and low C-peptide: liver disease, hormone deficiency or an IGF-2 tumour (often with low IGF-1); ketones above 2.7 mmol/L also point away from excess insulin.

How is hypoglycaemia treated?

The rule of 15 (15-15 rule)

For a person who is awake and can swallow, glucose is the preferred treatment (ADA). NIDDK's steps:

  1. If glucose is below 3.9 mmol/L (or below your personal target), take 15 to 20 grams of glucose or carbohydrate: 4 glucose tablets or 1 tube of glucose gel, about 120 mL (half a small glass) of regular fruit juice, 120 to 180 mL (half a can) of regular fizzy drink, or 1 tablespoon (15 mL) of sugar, honey or corn syrup.
  2. Wait 15 minutes and check again.
  3. If you are still low, repeat step 1 until you are back in range.
  4. If your next meal is more than 1 hour away, eat a snack such as crackers or fruit.

With kidney disease, avoid orange juice because of its potassium. With acarbose-type medicines, use glucose tablets or gel. Avoid high-fat or high-protein foods such as chocolate for the first treatment (ADA). With automated insulin delivery, 5 to 10 grams is often enough (ADA).

Severe hypoglycaemia: glucagon

If the person cannot swallow safely or is unconscious, put nothing in their mouth. Glucagon makes the liver release stored glucose; the ADA recommends it for everyone on insulin or at high risk, preferably a product that needs no mixing:

  • nasal glucagon powder (Baqsimi);
  • ready-to-use glucagon injection, for example in an autoinjector (Gvoke HypoPen);
  • dasiglucagon (Zegalogue), a glucagon analogue first approved in 2021 (ChEMBL).

In a 2023 comparison of 10 trials, all three ready-to-use products restored glucose in more than 98% of people, in about 14 minutes on average. Nausea and vomiting are common afterwards (Cleveland Clinic). Call 999 after giving it, and never give insulin to someone who is low.

After the episode

Every level 2 or level 3 episode is a signal to review treatment with your care team, who may lower doses, switch medicines or relax your targets.

Hypoglycaemia unawareness

With repeated lows, warning signs such as shakiness appear later or not at all, and the first sign may be confusion. A 2023 meta-analysis of 62 studies (39,180 people, 21 countries) found impaired awareness in 23% to 26% of people with diabetes on standard questionnaires, more often in type 1 diabetes and with longer disease duration. The ADA advises yearly screening; several weeks of avoiding lows, often by relaxing glucose goals for a while, can partly restore warning symptoms.

CGM alarms

A CGM measures glucose under the skin about every 5 minutes and can sound an alarm when glucose drops below a set point (MedlinePlus). The ADA recommends CGM for anyone at high risk. A CGM can reveal lows you do not feel, something an HbA1c result cannot show.

Preventing low blood sugar

  • Check glucose regularly, including before driving and before, during and after exercise.
  • Carry fast-acting sugar and, if prescribed, glucagon (check its expiration date).
  • Do not skip meals on insulin or sulfonylureas, and eat when you drink alcohol.
  • Teach family, friends and coworkers the signs and how to use glucagon, and wear a medical ID.
  • Ask which of your medicines can cause lows. See also our fasting glucose guide.

Hypoglycaemia in older adults, pregnancy, children and newborns

Older adults

Older adults may be less able to recognise symptoms and communicate their needs, the ADA notes, and cognitive impairment and hypoglycaemia feed each other. For older adults using CGM, the ADA sets a stricter limit: no more than 1% of the time (about 15 minutes a day) below 3.9 mmol/L.

Pregnancy

According to the ADA Standards 2025, pregnant people with type 1 diabetes have a higher risk of hypoglycaemia in the first trimester and after delivery, and pregnancy may blunt warning symptoms. Glucose targets are tighter (fasting below 95 mg/dL, or 5.3 mmol/L), and a CGM reading below 3.5 mmol/L (63 mg/dL) counts as low. Our article on blood tests during pregnancy lists the routine checks.

Children and newborns

Children usually need fewer grams of carbohydrate to treat a low; ask their diabetes team, and make sure school staff know where glucagon is kept. Low blood sugar affects up to 15% of newborns, especially babies of mothers with diabetes, and experts still disagree on exact treatment thresholds (2023 review).

Hypoglycaemia and driving

The ADA advises avoiding driving with hypoglycaemia. A 2024 study of 618 car trips by older drivers with type 1 diabetes supports checking that glucose is above 5.0 mmol/L (90 mg/dL) before driving: no trip started above that level had a CGM low on the road, while 11 of the 41 trips started at or below it did. If you feel low at the wheel, stop in a safe place and treat it first.

When to see a doctor

Call 999 if someone is unconscious, having a seizure or cannot swallow safely, right after giving glucagon (or at once if there is none), or if symptoms do not improve after sugar; MedlinePlus advises not driving yourself to the A&E.

See your doctor soon after any level 2 or level 3 episode, for frequent or nighttime lows, or if your warning symptoms are fading. Without diabetes, see a doctor for repeated shakiness, sweating or confusion, especially when fasting or after weight-loss surgery.

Latest scientific advances in hypoglycaemia

Ready-to-use glucagon works fast (2023)

A systematic review and indirect comparison in Diabetes Therapy pooled 10 trials of nasal glucagon, ready-to-use glucagon injection and dasiglucagon. All three restored glucose in more than 98% of people. Because they need no mixing, the ADA now prefers them.

Weekly insulin with fewer serious lows (2025)

In the QWINT-1 trial (NCT05662332, 795 adults with type 2 diabetes starting insulin), once-weekly insulin efsitora at fixed doses lowered HbA1c as well as daily insulin glargine. The rate of level 2 or level 3 hypoglycaemia was lower: 0.50 versus 0.88 events per person-year.

Stem cell-derived islets for severe hypoglycaemia (2025)

In the phase 1-2 FORWARD study of zimislecel (NCT04786262) all 12 people with type 1 diabetes who received the full dose were free of severe hypoglycaemic events from day 90 to day 365, and 10 of them no longer needed insulin at 1 year. The therapy requires immunosuppressive drugs, two deaths occurred (cryptococcal meningitis and progression of preexisting dementia), and it remains experimental.

New drugs for post-bariatric hypoglycaemia (2024-2026)

The UK Society for Endocrinology published guidelines on post-bariatric hypoglycaemia in 2024. A 2025 systematic review found that acarbose, pasireotide, empagliflozin and anakinra may reduce lows, but the evidence is weak. A phase 3 trial of avexitide (exendin 9-39), which blocks the receptor of the gut hormone GLP-1 according to the ChEMBL database, is underway in 75 participants (NCT06747468, primary completion expected in July 2026).

Which tests can help?

  • A lab plasma glucose and, with diabetes, CGM time below range.
  • HbA1c or fructosamine for the overall picture of glucose control.
  • Kidney and liver tests, since organ failure raises the risk of lows.
  • During a low without diabetes: insulin, C-peptide, proinsulin, beta-hydroxybutyrate and a sulfonylurea screen.
  • Morning cortisol, thyroid tests and, in selected cases, IGF-1 and IGF-2. Our diabetes blood test guide summarizes the core panel.

Glossary

  • Hypoglycaemia: low blood glucose, below 3.9 mmol/L (70 mg/dL) in people with diabetes.
  • Whipple triad: low glucose, matching symptoms and relief with glucose; required before a workup in people without diabetes.
  • Glucagon: a hormone that makes the liver release stored glucose; given as an emergency nasal spray or injection.
  • C-peptide: a fragment released with the body's own insulin, used to tell natural from injected insulin.
  • Beta-hydroxybutyrate: the main blood ketone; it stays low when insulin is high.

Frequently asked questions

How is hypoglycaemia treated?

With the rule of 15: 15 grams of fast-acting glucose, a recheck after 15 minutes, and a repeat if still below 3.9 mmol/L. If the person cannot swallow safely, use glucagon and call 999.

What are the possible causes of consistent low blood sugar without diabetes?

Excess insulin (insulinoma, post-bariatric hypoglycaemia, insulin antibodies, hidden use of diabetes drugs) or causes with low insulin (alcohol, adrenal insufficiency, organ failure, sepsis, IGF-2 tumours, some medicines). Blood drawn during an episode tells them apart.

How many glucose tablets should I take if my blood sugar is low?

NIDDK lists 4 glucose tablets as one dose of 15 to 20 grams. Tablet sizes vary, so check the grams on the label. Recheck after 15 minutes and repeat if still low.

What is reactive hypoglycaemia?

It is a low that occurs 2 to 4 hours after a meal, often a high-sugar or refined-carbohydrate meal, and most often after gastric bypass or sleeve surgery. After surgery, experts advise less than 30 grams of complex carbohydrates per meal and avoiding simple sugars.

What is the difference between hypoglycaemia and hyperglycaemia?

Hypoglycaemia is glucose below 3.9 mmol/L and comes on quickly with shakiness, sweating and confusion. Hyperglycaemia is glucose above your target range, often with thirst and frequent urination; it builds more slowly and can lead to emergencies such as the hyperosmolar hyperglycaemic state (HHS). Lows are treated with sugar, highs with the treatment your doctor prescribes.

Does type 1 diabetes cause hypoglycaemia or hyperglycaemia?

Both. Untreated type 1 diabetes causes hyperglycaemia because the body no longer makes insulin. Insulin treatment brings glucose down, but if the dose does not match food and activity, it causes hypoglycaemia.

Sources

  • American Diabetes Association Professional Practice Committee — 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes-2025 — Diabetes Care, 2025 — doi.org
  • American Diabetes Association Professional Practice Committee — 15. Management of diabetes in pregnancy: Standards of Care in Diabetes-2025 — Diabetes Care, 2025 — doi.org
  • Palani G, Stortz E, Moheet A — Clinical presentation and diagnostic approach to hypoglycemia in adults without diabetes mellitus — Endocr Pract, 2023 — doi.org
  • Looi E, Lawler HM — Non-diabetic hypoglycemia: evaluation and management in adults — J Clin Med, 2025 — doi.org
  • Popa SG, Golli AL, Matei CF et al. — Pancreatic neuroendocrine tumors: diagnostic pitfalls of non-diabetic severe hypoglycemia. Literature review and case report — Diagnostics (Basel), 2025 — doi.org
  • Zhang H, Yuan MX, Pan Q et al. — Insulin autoimmune syndrome: a Chinese expert consensus statement — Aging Med, 2025 — doi.org
  • Lawler HM, McGinnis T, Patti ME — Diagnosis and management of post-bariatric hypoglycemia — J Am Board Fam Med, 2025 — doi.org
  • Hazlehurst J, Khoo B, Lobato CB et al. — Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia — Endocr Connect, 2024 — doi.org
  • Sridharan K, Sivaramakrishnan G — Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies — Diabetol Metab Syndr, 2025 — doi.org
  • Giménez M, Khunti K, Matsuhisa M et al. — Systematic literature review and indirect treatment comparison of three ready-to-use glucagon treatments for severe hypoglycemia — Diabetes Ther, 2023 — doi.org
  • Yu X, Fan M, Zhao X et al. — Prevalence of impaired awareness of hypoglycaemia in people with diabetes mellitus: a systematic review and meta-analysis from 21 countries and regions — Diabet Med, 2023 — doi.org
  • Zhang Q, Zhou H, Lin R et al. — Risk factors for hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis — BMC Endocr Disord, 2025 — doi.org
  • Rosenstock J, Bailey T, Connery L et al. — Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy — N Engl J Med, 2025 — doi.org
  • Reichman TW, Markmann JF, Odorico J et al. — Stem cell-derived, fully differentiated islets for type 1 diabetes — N Engl J Med, 2025 — doi.org
  • Kwon HJ, Trawley S, Vogrin S et al. — Driving-related glucose patterns among older adults with type 1 diabetes — Diabetes Technol Ther, 2024 — doi.org
  • Roeper M, Hoermann H, Kummer S, Meissner T — Neonatal hypoglycemia: lack of evidence for a safe management — Front Endocrinol, 2023 — doi.org
  • ClinicalTrials.gov — Phase 3 study of avexitide in participants with post-bariatric hypoglycemia (NCT06747468) — clinicaltrials.gov
  • NIDDK — Low blood glucose (hypoglycemia) — National Institutes of Health — niddk.nih.gov
  • MedlinePlus — Low blood sugar — National Library of Medicine, 2026 — medlineplus.gov
  • Cleveland Clinic — Hypoglycemia (low blood sugar) — 2026 — my.clevelandclinic.org
  • EMBL-EBI — ChEMBL: glucagon (CHEMBL5314341), dasiglucagon hydrochloride (CHEMBL4650274), glipizide (CHEMBL1073), avexitide (CHEMBL4297949) — ChEMBL — ebi.ac.uk
  • NHS — Low blood sugar (hypoglycaemia) — nhs.uk, 2026 — https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/

Further reading

Understand your lab results with AI DiagMe

A low glucose result, a puzzling insulin or C-peptide value or a CGM summary can be hard to interpret alone. AI DiagMe reads your blood test report in minutes, explains each value in plain language and suggests questions for your doctor. Upload your lab results to AI DiagMe for a clear, personal report.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practising hospital physicians in specialties such as haematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr Claude Tchonko is a haematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specialises in the management of haematological malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimisation of care pathways in onco-haematology.

    Author of a reference work, ‘Lymphoid Haematological Malignancies in Mali’, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Haematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Haematology and an inter-university diploma (DIU) in Onco-Haematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming soon